AstraZeneca wins cancer drug reprieve
AstrZeneca won a surprise and welcome reprieve when a US regulatory advisory panel recommended that its new cancer drug be approved as a last line treatment. The Food and Drug Administration panel
AstrZeneca won a surprise and welcome reprieve when a US regulatory advisory panel recommended that its new cancer drug be approved as a last line treatment. The Food and Drug Administration panel